G&S Capital’s NovoCure NVCR Stock Holding History

G&S Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-200	Closed	-$15K	–	241
2019 Q3	$15K	Buy	+200	New	+$16K	0.01%	155

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

G&S Capital's NVCR Position: Q2 2020 in Review

G&S Capital sold out of NovoCure (NVCR) in Q2 2020, closing a stake of 200 shares — an estimated $13K sold.

G&S Capital first reported a position in NVCR in Q1 2019 and held it in 5 quarters. The position peaked at $16K in Q4 2019. 264 funds tracked by Wall St. Rank hold NVCR as of Q2 2020.

G&S Capital reported no remaining NovoCure position as of Q2 2020 after selling out during the quarter.
G&S Capital sold 200 NovoCure shares in Q2 2020, an estimated $13K.
G&S Capital first reported a position in NovoCure in Q1 2019 and held it in 5 quarters.
G&S Capital's NovoCure position peaked at $16K in Q4 2019.
264 funds tracked by Wall St. Rank held NovoCure as of Q2 2020.

Based on G&S Capital's 13F filing for Q2 2020, filed 24 Jul 2020.